$15.93 Million in Sales Expected for Agios Pharmaceuticals Inc (AGIO) This Quarter

Share on StockTwits

Analysts expect that Agios Pharmaceuticals Inc (NASDAQ:AGIO) will report sales of $15.93 million for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Agios Pharmaceuticals’ earnings. The highest sales estimate is $20.10 million and the lowest is $13.80 million. Agios Pharmaceuticals posted sales of $11.36 million during the same quarter last year, which suggests a positive year-over-year growth rate of 40.2%. The business is expected to issue its next earnings report on Wednesday, November 7th.

According to Zacks, analysts expect that Agios Pharmaceuticals will report full-year sales of $85.36 million for the current year, with estimates ranging from $81.93 million to $95.10 million. For the next financial year, analysts forecast that the company will post sales of $111.32 million per share, with estimates ranging from $79.28 million to $140.50 million. Zacks’ sales calculations are a mean average based on a survey of analysts that cover Agios Pharmaceuticals.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($1.19) EPS for the quarter, topping the consensus estimate of ($1.62) by $0.43. Agios Pharmaceuticals had a negative return on equity of 51.71% and a negative net margin of 462.08%. The firm had revenue of $40.40 million for the quarter, compared to the consensus estimate of $12.47 million. During the same quarter last year, the company earned ($1.78) earnings per share. The business’s revenue for the quarter was up 257.5% compared to the same quarter last year.

Several research analysts have recently commented on the company. Piper Jaffray Companies set a $125.00 price objective on Agios Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 2nd. BidaskClub downgraded Agios Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, June 18th. Needham & Company LLC reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a research note on Thursday, August 2nd. ValuEngine downgraded Agios Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, September 11th. Finally, Citigroup assumed coverage on Agios Pharmaceuticals in a research note on Wednesday, May 23rd. They issued a “buy” rating and a $117.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Agios Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $97.90.

In related news, insider Scott Biller sold 3,000 shares of Agios Pharmaceuticals stock in a transaction that occurred on Thursday, July 5th. The stock was sold at an average price of $83.50, for a total transaction of $250,500.00. Following the sale, the insider now owns 60,196 shares of the company’s stock, valued at approximately $5,026,366. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Steven L. Hoerter sold 2,050 shares of Agios Pharmaceuticals stock in a transaction that occurred on Friday, June 22nd. The shares were sold at an average price of $97.58, for a total value of $200,039.00. Following the sale, the insider now directly owns 2,050 shares in the company, valued at approximately $200,039. The disclosure for this sale can be found here. Insiders have sold a total of 30,677 shares of company stock worth $2,412,335 in the last three months. 3.02% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of AGIO. Lord Abbett & CO. LLC raised its stake in Agios Pharmaceuticals by 175.8% during the 1st quarter. Lord Abbett & CO. LLC now owns 1,044,346 shares of the biopharmaceutical company’s stock valued at $85,407,000 after purchasing an additional 665,684 shares during the period. Baillie Gifford & Co. bought a new stake in Agios Pharmaceuticals in the 1st quarter worth approximately $47,607,000. BlackRock Inc. increased its stake in Agios Pharmaceuticals by 14.0% in the 1st quarter. BlackRock Inc. now owns 3,206,053 shares of the biopharmaceutical company’s stock worth $262,192,000 after acquiring an additional 393,336 shares during the last quarter. Woodford Investment Management Ltd bought a new stake in Agios Pharmaceuticals in the 2nd quarter worth approximately $32,849,000. Finally, Wells Fargo & Company MN increased its stake in Agios Pharmaceuticals by 459.8% in the 2nd quarter. Wells Fargo & Company MN now owns 407,393 shares of the biopharmaceutical company’s stock worth $34,315,000 after acquiring an additional 334,617 shares during the last quarter. 93.64% of the stock is currently owned by institutional investors.

NASDAQ AGIO opened at $73.44 on Friday. Agios Pharmaceuticals has a 52 week low of $51.62 and a 52 week high of $99.82. The stock has a market capitalization of $4.30 billion, a PE ratio of -10.88 and a beta of 1.77.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.

Read More: Marijuana Stocks Future Looks Bright

Get a free copy of the Zacks research report on Agios Pharmaceuticals (AGIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

$15.93 Million in Sales Expected for Agios Pharmaceuticals Inc  This Quarter
$15.93 Million in Sales Expected for Agios Pharmaceuticals Inc This Quarter
Robert William Howard Sells 31,250 Shares of Jagged Peak Energy Inc  Stock
Robert William Howard Sells 31,250 Shares of Jagged Peak Energy Inc Stock
Crescent Point Energy Corp  Shares Bought by Van ECK Associates Corp
Crescent Point Energy Corp Shares Bought by Van ECK Associates Corp
OppenheimerFunds Inc. Purchases 46,544 Shares of Cintas Co.
OppenheimerFunds Inc. Purchases 46,544 Shares of Cintas Co.
DA Davidson Begins Coverage on Builders FirstSource
DA Davidson Begins Coverage on Builders FirstSource
Edap Tms  Cut to “Sell” at Zacks Investment Research
Edap Tms Cut to “Sell” at Zacks Investment Research


Leave a Reply

© 2006-2018 Ticker Report. Google+.